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DNA methyltransferases (DNMTs) are responsible for establishing and maintaining DNA methylation,
which are dysregulated in hepatitis C virus (HCV)-associated hepatocellular carcinoma (HCC). In this
report, using lentivirus-mediated shRNA interference technology, we identiﬁed DNMT1 and DNMT3B as
host factors involved in HCV propagation. Our results demonstrated that down-regulation of DNMT1 or
DNMT3B expression in Huh7.5.1 cells severely impaired cell culture-produced HCV (HCVcc) infection.
Furthermore, knockdown of DNMT1 or DNMT3B did not affect HCV entry and internal ribosome entry
site (IRES)-directed translation but did inhibit subgenomic replication. In contrast, knockdown of
DNMT3A had no signiﬁcant effect on HCV infection, entry, translation, or replication, which suggested
that DNMT3A did not play a signiﬁcant role in HCV life cycle. Moreover, we showed that DNMT inhibitors
5-Aza-C and 5-Aza-dC signiﬁcantly suppressed HCVcc infection, viral RNA replication, and protein
expression. These results suggest that DNMTs are critical for HCV replication and may represent potent
targets for the treatment of HCV infection.
& 2013 Elsevier Inc. All rights reserved.Introduction
Hepatitis C virus (HCV) is an enveloped positive-strand RNA virus
classiﬁed within the Hepacivirus genus in the Flaviviridae family. The
viral genome structure includes a 5′ untranslated region that func-
tions as an internal ribosome entry site (IRES), an open reading frame
that encodes structural (core, E1, E2, and p7) and non-structural
(NS2, NS3, NS4A, NS4B, NS5A, and NS5B) proteins, and a 3′
untranslated region (Moradpour et al., 2007). Approximately 130
million people are infected with HCV worldwide, and about 80% of
these infected individuals develop persistent infection, which is a
major cause of chronic hepatitis, liver cirrhosis, and hepatocellular
carcinoma (Hoofnagle, 2002; Poenisch and Bartenschlager, 2011;
Shepard et al., 2005). HCV infection is a major health problem, and
there is no protective vaccine available. Although the protease
inhibitors telaprevir and boceprevir were recently approved by the
US Food and Drug Administration (FDA), therapeutic approaches
remain limited for certain patient groups, including those with
unfavorable IL28B genotypes, HIV or HBV co-infection, and advanced
liver disease.
HCV encodes only 10 proteins, and host factors are known
to play an important role in the life cycle of HCV infection.
The interactions between virus and host factors determine thell rights reserved.outcome of HCV infection. In the past decade, the development of
replicons, retroviral pseudotyped particles (HCVpp), and infectious
HCV cell culture (HCVcc) systems have provided major break-
throughs for understanding the HCV life cycle and virus–host
interactions (Bartosch et al., 2003; Lohmann et al., 1999; Wakita
et al., 2005). Many host factors involved in HCV infection have
been identiﬁed, and each of these represents a potential thera-
peutic target. For instance, Cyclophilin A is a critical host factor for
HCV infection (Ciesek et al., 2009; Kaul et al., 2009), and its
inhibitors cyclosporine A, NIM-811, or Debio-25 can suppress HCV
genome replication (Ma et al., 2006; Paeshuyse et al., 2006).
Furthermore, inhibitors targeting essential host factors can over-
come HCV genotype-speciﬁc limitation and the selection of drug-
resistant mutants due to high sequence variation.
DNA methyltransferases (DNMTs) are responsible for establish-
ing and maintaining DNA methylation in mammalian cells. There
are at least three functional DNMTs, including DNMT1, DNMT3A,
and DNMT3B. DNMT1 is a maintenance methyltransferase and is
responsible for the maintenance of established patterns of methy-
lated DNA following DNA replication. DNMT3A and DNMT3B are
de novo methyltransferases and are responsible for the establish-
ment of DNA methylation patterns in the early stages of mamma-
lian development and cellular differentiation (Bestor, 2000;
Jurkowska et al., 2011). Aberrant expression of DNMTs contributes
to the initiation and progression of various human cancers
(Feinberg and Tycko, 2004; Jones and Baylin, 2007), and increased
DNMT activity leads to the hypermethylation of many tumor
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are generally associated with transcriptional repression and
thereby contribute to gene regulation (Lopez-Serra and Esteller,
2011; Portela and Esteller, 2010). Existing evidence indicates that
the expression of DNMTs is signiﬁcantly higher in hepatocellular
carcinoma (HCC) tissues as compared to nontumor tissues (Fan
et al., 2009; Saito et al., 2003), and inactivation of tumor suppres-
sor genes by hypermethylation is an important epigenetic altera-
tion in HCV-related HCC (Nishida et al., 2008; Yang et al., 2003).
Moreover, HCV core protein has been shown to down regulate
E-cadherin and p16 expression via activation of DNMT1 and
DNMT3B (Arora et al., 2008; Park et al., 2011).
DNA methylation that silences gene expression is a reversible,
stepwise process. The two most potent DNMT inhibitors, 5-Aza-C
and 5-Aza-dC, have been shown to inhibit DNMT activity by
incorporating into DNA to form an irreversible covalent complex
with DNMTs (Santi et al., 1984) or by triggering DNMT1 degrada-
tion through the proteasomal pathway (Ghoshal et al., 2005).
Furthermore, 5-Aza-C and 5-Aza-dC can reactivate tumor suppres-
sor genes silenced by promoter methylation, which provides an
alternate approach for cancer therapy. Consistently, knockdown of
DNMTs by RNA interference has been reported to cause demethy-
lation and re-expression of silenced tumor suppressor genes (Leu
et al., 2003; Robert et al., 2003).
However, the speciﬁc biological functions of DNMTs during HCV
infection remain poorly understood. We hypothesized that these
DNMTs might play a role in HCV infection. In this study, we examined
HCV infection in cells rendered defective for DNMTs by shRNA
interference or by pharmacological inhibition, and we demonstrated
that down-regulation of the expression of DNMT1 or DNMT3B in
Huh7.5.1 cells severely impaired HCVcc infection, viral RNA replication,
and protein expression. Moreover, the DNMT inhibitors 5-Aza-C and
5-Aza-dC signiﬁcantly inhibited HCV infection.Results and discussion
Knockdown of DNMT1 or DNMT3B severely impairs HCV infection
To assess the biological functions of DNMTs during HCV infec-
tion, we prepared a panel of Huh7.5.1 cells in which we stably
knocked down the expression of DNMT1, DNMT3A, DNMT3B, O-6-
methylguanine-DNA methyltransferase (MGMT), tRNA aspartic acid
methyltransferase 1 (TRDMT1), or CD81 by lentivirus vector pLKO.1-
mediated RNA interference. The Scramble shRNA expressing non-
targeting shRNA and pLKO.1 vector containing non-hairpin insert
sequence were used as negative controls. CD81 shRNA was used as
a positive control because CD81 is an indispensable receptor for
HCV infection. Real-time quantitative RT-PCR analysis showed that
the mRNA levels of the target genes were reduced by 60%–80% in
the corresponding knockdown cells (Fig. S1).
We ﬁrst used the GFP reporter virus J399EM to quantify the
effect of DNMT knockdown on HCV infection. The HCV infection
was quantiﬁed by counting GFP-expressing cells using ﬂow cyto-
metry. The shRNA knockdown cells were infected with the J399EM
virus at an MOI of 0.1 and analyzed by ﬂow cytometry for GFP-
expressing cells at 72 h post-infection. As shown in Fig. 1, in
comparison to Scramble control-transduced cells, GFP-expressing
cells were reduced by 71% and 92% in DNMT1 and DNMT3B
knockdown cells, respectively. However, knockdown of DNMT3A
had little effect on HCV infection. These results suggested that
HCV infection was signiﬁcantly reduced in DNMT1 or DNMT3B
knockdown cells. In contrast, highly efﬁcient knockdown of other
unrelated methyltransferases (MGMT and TRDMT1) had no obser-
vable effect on HCV infection, suggesting that our ﬁndings were not
due to a nonspeciﬁc event.The expression of HCV proteins was also examined in DNMT
knockdown cells that were infected with unmodiﬁed JFH1 virus
(MOI of 0.1). The efﬁciency of stable RNA interference-mediated
knockdown of DNMT1, DNMT3A, and DNMT3B protein expression
was also determined by Western blot analysis (Fig. 2A–C).The
expression of Core, NS3, and NS5A proteins was dramatically
suppressed in DNMT1 or DNMT3B knockdown cells (Fig. 2A and
C). Consistent with the observed changes in protein expression,
HCV RNA levels were also signiﬁcantly reduced, by 82% and 94% in
DNMT1 and DNMT3B knockdown cells, respectively (Fig. 2D).
However, the expression of HCV proteins and RNA was completely
unaffected by knockdown of DNMT3A expression (Fig. 2B and D).
Overall, these results indicated that DNMT1 and DNMT3B were
required for HCV infection, protein expression, and RNA synthesis.
Knockdown of DNA methyltransferases does not affect HCV entry
Inhibition of HCV infection by knockdown of DNMT1 or
DNMT3B indicated that DNMTs may play an important role in viral
entry, translation, or replication. To deﬁne the step(s) at which
DNMTs were required for HCV infection, we ﬁrst analyzed the role
of DNMTs in HCV entry by comparing the number of viruses that
had entered into cells to the number of viruses remaining in the
media, as previously described (Chen et al., 2012; Tao et al., 2009).
Brieﬂy, DNMT1, DNMT3A, DNMT3B, and Scramble knockdown cells
were incubated with J399EM virus at an MOI of 0.2. The inocula
were collected at the indicated time points, and the cells were
cultured in fresh complete medium. The number of virions that had
entered the cells and the number of remaining virions in the cell
culture supernatant at each time point after inoculation were
determined, respectively. As shown in Fig. 3A, as the incubation
time increased, we observed a consistent increase in the number of
infected cells in the Scramble (48.3%–99.6%), DNMT1 (5.1%–26.8%),
DNMT3A (44.7%–97.3%), and DNMT3B (6.1%–25.1%) knockdown
cells, but the number of HCV infected cells reduced in DNMT1 or
DNMT3B knockdown cells as compared to DNMT3A and Scramble
knockdown cells at each time point. Furthermore, the number of
infection cells incubated with the remaining virions decreased in all
knockdown cells as the incubation time increased, but the number
of HCV infected cells was comparable at each time point (Fig. 3B).
These results suggested that DNMTs did not affect HCV entry. The
reduction of HCV infection in DNMT1 or DNMT3B knockdown cells
was likely due to interference with a post-entry step of HCV
infection.
To further conﬁrm this result, we investigated the infection of
HCVpp in the DNMT knockdown cells. As shown in Fig. 3C, no
signiﬁcant difference in HCVpp infection was observed between
DNMT1, DNMT3A, DNMT3B, and Scramble knockdown cells. Together,
these results demonstrated that knockdown of DNMTs had no effect
on the HCV entry step.
Knockdown of DNA methyltransferases does not affect HCV IRES-
directed translation
We further investigated whether knockdown of DNMTs expression
would affect HCV IRES-directed translation. A transient transfection
assay was conducted using a dual-luciferase reporter gene construct
containing the HCV IRES element (Chen et al., 2012). This reporter
plasmid was designed to indicate the level of HCV IRES-directed
translation, in which the translation of the upstream Renilla luciferase
gene (Rluc) was mediated by the 5′ cap structure and the downstream
Fireﬂy luciferase gene (Fluc) was controlled by an HCV IRES element
(Fig. 4A). As shown in Fig. 4B, no signiﬁcant difference was observed in
the DNMT1, DNMT3A, DNMT3B, Scramble, and pLKO.1 knockdown
cells. This result suggested that knockdown of DNMTs expression had
minimal impact on HCV IRES-directed translation.
Fig. 1. The effects of DNMT knockdown on HCV infection. (A) The knockdown cell lines were infected with the J399EM virus at an MOI of 0.1. HCV infection was determined
by counting GFP-expressing cells using ﬂow cytometry at 72 h post-infection. Scramble shRNA and pLKO.1 were used as negative controls. CD81 shRNAwas used as a positive
control. (B) Statistical analysis of GFP-expressing cells as shown in (A), and the results are expressed as percentages of the levels in cells expressing nontargeting Scramble
shRNA. The results are expressed as means and standard deviations from three independent experiments performed in triplicate. n Po0.01 for treated versus control cells.
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replication
We further assessed the effect of DNMT knockdown on HCV
replication in Con1 subgenomic replicon (Con1-SGR) cells, which
were derived from Huh7-Lunet cells that stably express the Con1-
based selectable subgenomic replicon. Con1-SGR cells were
infected with lentivirus particles expressing pLKO.1, Scramble,
DNMT1, DNMT3A, or DNMT3B shRNA. After 72 h of transduction,
the cells were harvested and analyzed by Western blot and real-
time quantitative RT-PCR. As shown in Fig. 5A and C, the expres-
sion levels of HCV NS3 and NS5A proteins were severely reduced
in the cells where the expression of DNMT1 or DNMT3B protein
was down-regulated. Consistent with the observed effects on
protein expression, the amounts of HCV subgenomic replicon
RNA were also signiﬁcantly reduced, by 66% and 86% in DNMT1
and DNMT3B knockdown cells, respectively (Fig. 5D). However,
no difference between HCV protein and RNA expression was
observed in DNMT3A knockdown cells (Fig. 5B and D). Theseresults demonstrated that knockdown of DNMT1 or DNMT3B
severely impaired HCV replication.
DNA methyltransferase inhibitors inhibit HCV infection
Inhibitors that target cellular enzymes represent an alternative
approach for inhibiting HCV infection and have the advantage of a
low likelihood of drug resistance as compared to inhibitors that
target viral proteins (Georgel et al., 2010). 5-Aza-C and 5-Aza-dC are
the best-known DNMT inhibitors. Therefore, we initially examined
the effects of 5-Aza-C on HCV infection using the J399EM virus.
As shown in Fig. 6A and B, 5-Aza-C signiﬁcantly decreased the
number of GFP-expressing cells in a dose-dependent manner with
an EC50 of 1.2 μM. HCV infection was largely inhibited at a
concentration of 5 μM 5-Aza-C, with an inhibition rate of 91.5%.
The anti-HCV activity of 5-Aza-C and 5-Aza-dC in Huh7.5.1 cells
infected with unmodiﬁed JFH1 virus was also examined. Real-time
quantitative RT-PCR analysis indicated that the levels of HCV RNA
were dramatically reduced following treatment with 5-Aza-C
Fig. 2. The effects of DNMT knockdown on HCV protein expression and RNA synthesis. (A to C) The knockdown cell lines were infected with the JFH1 virus at an MOI of
0.1 and harvested at 72 h post-infection. The expression of HCV Core, NS3, and NS5A proteins was detected by Western blot, and β-actin and α-tubulin levels served as
internal controls. Expression levels were measured in (A) DNMT1 shRNA knockdown cells, (B) DNMT3A shRNA knockdown cells, and (C) DNMT3B shRNA knockdown cells.
MGMT shRNA, TRDMT1 shRNA, Scramble shRNA, and pLKO.1 cell lines were used as controls. (D) The intracellular HCV RNA levels were detected by real-time quantitative
RT-PCR and normalized to the cellular GAPDH mRNA levels in the indicated shRNA knockdown cell lines. The data are expressed as a percentage of the Scramble control
samples. The results are expressed as means and standard deviations from three independent experiments performed in triplicate. n Po0.01 for treated versus control cells.
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which was used as a positive control (Fig. 6D). Furthermore,
Western blot analysis showed that HCV Core, NS3, and NS5A
protein levels were also remarkably suppressed following treat-
ment with 5-Aza-C or 5-Aza-dC (Fig. 6E). Moreover, we found that
DNMT1 protein was degraded following treatments with 5-Aza-C
or 5-Aza-dC (Fig. 6E), which is similar to the results of a previous
report showing that 5-Aza-dC could induce degradation of DNMT1
(Ghoshal et al., 2005). Cytotoxicity effects were not observed at the
concentration of 5 μM 5-Aza-C (Fig. 6C) and 5-Aza-dC (data not
shown) in Huh7.5.1 cells by using the cell counting kit-8 (CCK-8)
cytotoxicity assay. Taken together, these results indicated that the
DNMT inhibitors 5-Aza-C and 5-Aza-dC signiﬁcantly inhibited HCV
infection, RNA synthesis, and protein expression.
In summary, we demonstrated that DNMT1 and DNMT3B were
required for HCV propagation. Knockdown of DNMT1 or DNMT3B
impaired HCV infection and genome replication (Figs. 1, 2, and 5)
but did not affect HCV entry and translation (Figs. 3 and 4).
Although DNMT1 is a maintenance methyltransferase, DNMT3A
and DNMT3B are de novo methyltransferases; however, promoter
hypermethylation and gene silencing may involve cooperation
between DNMTs. For example, DNMT1 is not sufﬁcient for the
maintenance of abnormal hypermethylation and cooperates with
DNMT3B to silence genes in human cancer cells (Rhee et al., 2002),
and double RNA interference of DNMT1 and DNMT3B was shown
to enhance DNA demethylation and gene reactivation (Leu et al.,
2003). We hypothesized that the role of DNMT1 and DNMT3B in
maintaining abnormal hypermethylation might contribute to HCV
infection. Moreover, the expression levels of DNMT1 and DNMT3Bwere increased in HCV core-expressing cells (Arora et al., 2008;
Benegiamo et al., 2012). Although identifying the mechanism
responsible for the inhibition of HCV infection by knockdown of
DNMT1 or DNMT3B expression requires further study, we inferred
that DNMT1 and DNMT3B might indirectly regulate HCV infection
by regulating the expression of host factors essential for HCV
propagation. For instance, interferon-stimulated genes (ISGs),
which are known to be involved in the anti-HCV activity of IFN,
are epigenetically silenced by DNA methylation in interferon-
resistant HCV replicon-harboring cells, and these ISGs can be
upregulated by 5-Aza-C treatment (Naka et al., 2006).
The DNMT inhibitors 5-Aza-C and 5-Aza-dC showed signiﬁcant
suppressive effects on HCV infection, RNA synthesis, and protein
expression (Fig. 6). 5-Aza-C can be incorporated into DNA or RNA,
while 5-Aza-dC can only be incorporated into DNA (Yang et al., 2010).
As HCV is RNA virus, we inferred that the antiviral activity of 5-Aza-C
and 5-Aza-dC against HCV was not due to incorporation into RNA.
Furthermore, 5-Aza-C and 5-Aza-dC not only decreased DNMT activity
but also induced the degradation of DNMT1 proteins (Fig. 6E), which
further indicates that DNMTs may play an important role in HCV
infection. 5-Aza-C and 5-Aza-dC have been approved by the US Food
and Drug Administration (FDA) for the treatment of myelodysplastic
syndrome (MDS) and are also being tested for the treatment of many
other solid cancers (Issa, 2007; Schrump et al., 2006). In addition,
5-Aza-C has also been shown to inhibit replication and induce lethal
mutagenesis in human immunodeﬁciency virus type 1 (HIV-1)
(Bouchard et al., 1990; Dapp et al., 2009). Therefore, 5-Aza-C and
5-Aza-dC represent a potential novel approach for the treatment of
HCV infection, HCV-associated HCC, and HCV/HIV co-infected patients.
Fig. 3. The effects of DNMT knockdown on HCV entry. (A and B) DNMT1, DNMT3A, DNMT3B, and Scramble shRNA knockdown cells were inoculated with the J399EM virus at
an MOI of 0.2. The inocula were withdrawn at the indicated time points and transferred to naïve Huh7.5.1 cells. (A) The number of virions that had entered into the cells was
quantiﬁed using ﬂow cytometry at 72 h post-infection. The data are expressed as the percentage of HCV-positive cells number to that at 9 h post-infection. (B) The number of
remaining virions in the withdrawn viral inocula at the indicated times was quantiﬁed using ﬂow cytometry at 72 h post-infection after re-infecting naïve Huh7.5.1 cells. The
data are expressed as the percentage of the total input. (C) The DNMT knockdown cells were infected with HCVpp for 48 h, and the lysates of the infected cells were assayed
for luciferase activity. The results are expressed as means and standard deviations from three independent experiments performed in triplicate.
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the molecular mechanisms involved in viral infection but also
enable the identiﬁcation of novel antiviral targets for preventive
and therapeutic strategies.Materials and methods
Cell culture and reagents
Huh7.5.1 and 293 T cells were routinely maintained in complete
DMEM containing 2 mM L-glutamine, 1% nonessential amino acids,
10 mM HEPES, and 10% fetal bovine serum (Invitrogen) at 37 1C in 5%
CO2. Con1-SGR cells are Huh7-Lunet cells that harbor the genotype
1b Con1 subgenomic replicon, which were created by transfecting in
vitro-transcribed pFKI389neo/NS3–3′ RNA into Huh7-Lunet cells and
selecting transfected cells with 0.5 mg/ml G418. Cells from a single
colony expressing a high level of the subgenomic replicon were
designated as Con1-SGR cells (Chen et al., 2012). Human interferon
alpha-2b (IFNα-2b) was purchased from Anke-Bio. 5-Aza-C and
5-Aza-dC were purchased from Sigma-Aldrich, dissolved in DMSO to
a concentration of 100 mM, and stored at −20 1C for subsequent use.
Generation of stable knockdown cells using a lentiviral shRNA system
For shRNA-mediated knockdown experiments, a lentiviral vector
pLKO.1 system was used to silence target gene expression. pLKO.1-
shRNA constructs expressing DNMT1 shRNA, DNMT3A shRNA,DNMT3B shRNA, MGMT shRNA, TRDMT1 shRNA and Scramble
shRNA (negative control) were purchased from Sigma-Aldrich.
293 T cells seeded in 6-well plates were transfected with either
pLKO.1-shRNA constructs (1 μg) or pLKO.1 (1 μg) along with the
packaging plasmids psPAX2 (0.5 μg) and pMD.2 G (0.5 μg) using the
FuGENE® HD Transfection Reagent (Roche). The shRNA lentiviral
stocks were harvested from the culture medium at 48 h post-
transfection and ﬁltered using a 0.45 μM ﬁlter. To select for
Huh7.5.1 cells that stably expressed the shRNA constructs,
Huh7.5.1 cells in 6-well plates were transduced with 200 μl of
shRNA lentiviral stocks in the presence of 4 μg/ml polybrene.
At 48 h post-transduction, the lentiviral-infected cells were selected
with 1 μg/ml puromycin for approximately 7 days. The surviving
colonies were pooled and maintained with 0.5 μg/ml puromycin.
Knockdown of gene expression was conﬁrmed by real-time quanti-
tative RT-PCR or Western blot analysis.
Production of HCVcc
The plasmid pJFH1, which contains the full-length genomic cDNA
sequence of the HCV genotype 2a strain JFH1, was kindly provided
by T. Wakita (Wakita et al., 2005). The plasmid pJ399EM was derived
from pJFH1 by inserting the EGFP gene into the NS5A region, and
J399EM produces infectious virus as robustly as JFH1 (Han et al., 2009).
JFH1 and J399EM viruses were produced as previously described (Kato
et al., 2006). Brieﬂy, HCV genomic RNA was generated by in vitro
transcription using linearized pJFH1 and pJ399EM plasmids as tem-
plates and was delivered to Huh7.5.1 cells by electroporation. At 15
Fig. 4. The effects of DNMT knockdown on HCV IRES-mediated transcription.
(A) A dual-luciferase reporter gene construct containing HCV IRES elements (5′UTR)
was used. (B) pLKO.1, Scramble, DNMT1, DNMT3A, and DNMT3B shRNA knockdown
cells were transiently transfected with the dual-luciferase reporter gene. Luciferase
assays were performed at 48 h post-transfection. The relative luciferase activity is
expressed as the ratio of Fireﬂy luciferase activity to Renilla luciferase activity. The
data are expressed as a percentage of the Scramble control samples. The error bars
represent the standard deviations from three independent experiments performed
in triplicate.
Fig. 5. The effects of DNMT knockdown on HCV subgenomic replication. Con1-SGR ce
DNMT3A, or DNMT3B shRNA for 72 h. HCV protein and RNA expression levels were dete
The data are expressed as a percentage of the Scramble control samples. The results are
performed in triplicate. n Po0.01 for treated versus control cells.
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for viral stock, and the viral titer was determined as described
previously (Han et al., 2009; Kato et al., 2006).
Production and infection of HCVpp
Murine leukemia virus (MLV)-based pseudotyped particles bearing
HCV E1E2 glycoprotein were generated as previously described (Chen
et al., 2012). Brieﬂy, 293 T cells were co-transfected with pVPack-GP,
pFB-luc, and HCV E1E2 expression plasmids. The culture mediumwas
collected for viral stock at 48 h post-transfection and ﬁltered using a
0.45 μM ﬁlter. For the infection assays, the knockdown cells in 24-well
plates were infected with pseudotyped viral stock for 48 h. The
infected cells were lysed with cell lysis buffer and subjected to
luciferase assays using the Luciferase Reporter Assay System
(Promega) according to the manufacturer's instructions.
Viral entry assay
The entry assay was performed as previously described (Chen et al.,
2012; Tao et al., 2009). In brief, DNMT1, DNMT3A, DNMT3B, and
Scramble shRNA knockdown cells were inoculated with J399EM virus
at an MOI of 0.2. The inocula were removed at the indicated time
points and transferred to 1105 naïve Huh7.5.1 cells in 12-well plates
to quantify the number of virions that had not entered into cells at
72 h post-infection. At the same time, the inoculated cells were
washed three times with PBS and cultured in fresh complete medium.
The cells were collected at 72 h post-infection and analyzed using ﬂow
cytometry to quantify the number of virions that had entered
into cells.lls were incubated with lentivirus particles expressing pLKO.1, Scramble, DNMT1,
cted using Western blot (A to C) and real-time quantitative RT-PCR (D), respectively.
expressed as means and standard deviations from three independent experiments
Fig. 6. The effects of DNMT inhibitors on HCV infection, RNA synthesis, and protein expression. (A) Huh7.5.1 cells were infected with the J399EM virus at an MOI of 0.1, and
the infected cells were immediately treated with various concentrations of 5-Aza-C. Then, HCV infection was measured by ﬂow cytometry analysis at 72 h post-infection.
(B) Statistical analysis of GFP-expressing cells as shown in (A), and these values are expressed as the percentage of DMSO-treated control values. (C) Huh7.5.1 cells were
treated with the indicated concentrations of 5-Aza-C for 72 h, and the cell viability was determined using a CCK-8 assay. (D, E) Huh7.5.1 cells were infected with the JFH1
virus at an MOI of 0.1 and then immediately treated with DMSO (control), 5-Aza-C (5 μM), 5-Aza-dC (5 μM), or IFNα-2b (100 U/ml). The intracellular HCV RNA levels were
determined using real-time quantitative RT-PCR and normalized to the cellular GAPDH mRNA levels at 72 h post-infection. The data are expressed as a percentage of the
Scramble control samples. The results are expressed as means and standard deviations from three independent experiments performed in triplicate. n Po0.01 for treated
versus control cells (D). The intracellular HCV Core, NS3, and NS5A proteins were analyzed using Western blot at 72 h post-infection. The expression of DNMT1 was also
detected, and β-actin and α-tubulin levels served as internal controls. Naïve Huh-7.5.1 cells were used as a negative control (E).
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The shRNA knockdown cell lines were seeded into 24-well
plates (approximately 5104 cells/well) and transfected with
0.5 μg of the HCV IRES dual-luciferase reporter plasmid (She
et al., 2008) using the FuGENE® HD Transfection Reagent (Roche).
At 48 h post-transfection, the cells were lysed in passive lyses
buffer and then subjected to dual-luciferase assays using theDual-Luciferase Reporter Assay System (Promega) according to
the manufacturer's instructions.
Real-time quantitative RT-PCR
For the real-time quantitative RT-PCR, total cellular RNA was
extracted from the cells using the RNeasy Mini Kit (Qiagen)
according to the manufacturer's instructions. Total RNA extract
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scription using random primers and M-MLV reverse transcriptase
(Takara). Real-time quantitative PCR was performed as previously
described using Platinum SYBR Green qPCR SuperMix-UDG with
ROX (Life Technologies) and the Applied Biosystems 7500 Real-
Time PCR System (Chen et al., 2012). HCV RNA genome quantiﬁca-
tion was determined according to the comparative CT (ΔΔCT)
method using GAPDH mRNA for internal normalization.
Western blot analysis
The protein preparation and the Western blot were performed
as previously described (Chen et al., 2012). In brief, an equal
amount of total protein was resolved by electrophoresis in 10% or
12% SDS-PAGE followed by transfer onto a PVDF membrane
(Millipore). The membrane was then incubated with the following
antibodies: mouse monoclonal antibodies against HCV core (C7-
50, Abcam), NS3 (provided by Prof. Chenyang Li, Henan Biotech-
nology Research Centre, China), NS5A (9E10), β-actin (Santa Cruz
Biotechnology), and α-tubulin (Santa Cruz Biotechnology); and
rabbit polyclonal antibodies against DNMT1, DNMT3A, and
DNMT3B (Santa Cruz Biotechnology). HRP-linked anti-mouse and
anti-rabbit immunoglobulin G antibodies (Cell Signaling Technol-
ogy) were used as the secondary antibody. Immunodetection was
performed using the Supersignal West Pico Chemiluminescent
Substrate (Thermo scientiﬁc) and the AlphaEase FC Imaging
System (Alpha Innotech Corporation).
Statistical analysis
The data are expressed as the means±SD of three independent
experiments performed in triplicate. The Student's t-test was used
to test for differences between the control and test samples.
Po0.05 was considered statistically signiﬁcant. All statistical
analyses were calculated using the SPSS statistical software,
version 17.0 (SPSS Inc. Chicago, IL, USA).Acknowledgments
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